Infections in secondary immunodeficiency patients treated with Privigen^® or Hizentra^®: a retrospective US administrative claims study in patients with hematological malignancies

Abstract

B cell-derived lymphoproliferative disorders are associated with secondary immunodeficiency (SID); some patients require immunoglobulin replacement therapy (IgRT) to mitigate infections. Using IQVIA's PharMetrics V R Plus database, patients with SID who received IgPro10/IgPro20 in the 12 months post-diagnosis (IgRT users) were matched to patients with SID not receiving IgRT (non-IgRT users). The risk of severe infection was compared using within-patient change from baseline to follow-up as well as between cohorts. Overall, 277 IgRT users were matched to 1019 non-IgRT users. Before IgRT, more IgRT users experienced any bacterial infection (88.4% vs. 72.9%; p<.0001) or !1 severe bacterial infection (SBI) (42.2% vs. 31.8%; p¼.0011) vs. non-IgRT users. During followup, risk of SBI among IgRT users (21.7%) reached parity with non-IgRT users (21.2%). IgRT was associated with a reduction in SBIs to levels comparable with the lower 'baseline infection risk' of non-IgRT users. These criteria help define SID patients who may benefit from IgRT.

Passive immunization against COVID-19 by anti-SARS-CoV-2 spike IgG in commercially available immunoglobulin preparations in severe antibody deficiency

“…Patients with antibody deficiency are at risk for bacterial and viral infections. 1,2 Regular immunoglobulin replacement therapy by intravenous or subcutaneous infusions reduces infection susceptibility. Immunoglobulin preparations containing highly enriched polyclonal IgG are derived from pooled plasma from greater than 10 3 donors to cover a broad range of pathogenspecific antibodies.…”